SOHO 2025 | The value of lower-intensity regimens in AML treatment

So, I think one of the wonderful things about the lower-intensity regimens, and particularly this oral regimen, is I think it’s really nice for patients. You know, when patients get a diagnosis of AML, it’s life-changing. You know, you all of a sudden have a life-threatening condition. You have to be in the hospital for a month often for induction. And then you’re in the hospital again with, you know, intensive therapies. There’s always the risk of getting neutropenic fever and those types of things. What’s really nice about these lower-intensity regimens, and particularly this, is if we can, this all-oral regimen might allow patients to not have to come back and come see the doctor as much as, you know, they would with other regimens. They can spend more time at home with family. And I think what’s, what will be really interesting to see with some of the kind of ongoing randomized trials is how some of these intensive regimens compare to lower-intensity regimens in that kind of more middle-age range. For our older patients, not good candidates for intensive therapy, these lower-intensity regimens with a little bit less myelosuppression are wonderful. But I think seeing what happens to that 50 to 60 age range where they might be a little bit younger, how do these compare? Could these regimens actually be non-inferior, particularly maybe to some of our patients that are going to transplant? And that is their goal. You know, if we’re able to get them into remission really, really successfully with these, does it matter if they got there through a lower-intensity regimen versus a higher-intensity regimen? And I think that’s, that will be really interesting going forward to see how some of that data pans out.

This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.